27 dic Mycovia Pharmaceuticals Announces Partnership with Gedeon Richter to Commercialize and Manufacture VT-1161 for Recurrent Vulvovaginal Cand
Agreement expands Mycovia’s worldwide commercialization plans for VT-1161 to European countries, Latin America, Australia, Russia and Commonwealth of Independent States
Mycovia will continue to quickly develop VT-1161 as a prospective first FDA-approved remedy for recurrent vulvovaginal candidiasis
DURHAM, N.C.–( COMPANY WIRE )–Mycovia Pharmaceuticals, Inc. today announced it offers entered into a license that is exclusive development and technology transfer agreement with Gedeon Richter Plc., located in Budapest, Hungary, to commercialize and produce VT-1161 in European countries, Latin America, Australia, Russia along with other CIS nations. VT-1161, an dental antifungal item prospect, happens to be in stage 3 medical studies for the remedy for Recurrent Vulvovaginal Candidiasis (RVVC), a debilitating, chronic infectious condition that impacts almost 138 million females global every year.
“We are excited to partner with Gedeon Richter, an organization with strong market leadership in women’s health, to build up and commercialize VT-1161, our prospective first FDA-approved treatment plan for RVVC,” said Patrick Jordan, CEO of Mycovia and Partner at NovaQuest Capital Management, which formed Mycovia in 2018 to advance VT-1161 in worldwide areas. (más…)